A proposal for validation of antibodies

  • Nat Methods. 2016 Oct;13(10):823-7. doi: 10.1038/nmeth.3995.
Mathias Uhlen  1 ,  Anita Bandrowski  2 ,  Steven Carr  3 ,  Aled Edwards  4 ,  Jan Ellenberg  5 ,  Emma Lundberg  1 ,  David L Rimm  6 ,  Henry Rodriguez  7 ,  Tara Hiltke  7 ,  Michael Snyder  8 ,  Tadashi Yamamoto  9
Affiliations
  • 1. Science for Life Laboratory, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.
  • 2. Center for Research in Biological Systems, University of California at San Diego, San Diego, California, USA.
  • 3. Proteomics Platform, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
  • 4. Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • 5. Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
  • 6. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • 7. Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • 8. Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.
  • 9. Biofluid Biomarker Center, Niigata University, Niigata, Japan.
PMID: 27595404 DOI: 10.1038/nmeth.3995
Abstract

We convened an ad hoc International Working Group for Antibody Validation in order to formulate the best approaches for validating antibodies used in common research applications and to provide guidelines that ensure antibody reproducibility. We recommend five conceptual ‘pillars’ for antibody validation to be used in an application-specific manner.